Verification register Bio, Health & Neuro
Current reading
Readiness band and full integer triple
AI-assisted assembly · derived results
Readiness band
Ready
Primary summary from verified readiness
- Confidence
- 86% · stale
- Computed at
- 2026-10-09T21:13:19.418186+00:00
- Claimed
- 55
- Reported
- 55
- Verified
- 55
- Gap
- 0
Public ambition and stated capability
Observed practitioner reporting
Independently supported evidence
Claimed and verified align
Evidence strength Strong
Decision
What the current evidence supports
Agent-assisted assessment · independently reviewed · 2026-10-09
Consider Zanvastro within specialist care for its US-approved Alexander disease indication.
- Why
- FDA-reviewed evidence supports motor-function benefit, while small age-specific samples and the recent launch leave long-term outcomes uncertain.
- Next
- Assess eligibility, lumbar-puncture capacity, coverage and safety monitoring with the treating specialist.
Constraints
Blockers
- Quarterly intrathecal administration requires experienced clinical staff.
- High acquisition cost may complicate coverage and access.
- Aseptic meningitis requires clinical vigilance.
- Long-term outcomes and direct infant efficacy evidence remain limited.
- Availability outside the US depends on future regulatory submissions and approvals.
Evidence summary
Derived counts
AI-assisted assembly
- Total
- 10
- Tier 1
- 4
- Tier 2
- 6
- Tier 3
- 0
- Supports
- 5
- Contradicts
- 2
- Context
- 3
- Latest observed
- 2026-09-07
Counts and dates only. Raw signals, private excerpts, trust records, and internal corpus material are not published here.
Publication record
Revisions
Revision 3
- 2026-09-21 Reading moved from ready to ready.
- 2026-09-30 Reading moved from ready to ready.
- 2026-10-01 Reading moved from ready to ready.